Purdue Pharma, Sackler Family $7.4 Billion Opioid Settlement Legally Effective, Michigan AG Nessel Announces | Zakar

Zakar/Cycles/Purdue Pharma, Sackler Fa...

🇮🇳

ACTIVE

Purdue Pharma, Sackler Family $7.4 Billion Opioid Settlement Legally Effective, Michigan AG Nessel Announces

A $7.4 billion opioid settlement involving Purdue Pharma and the Sackler family is now legally effective, as announced by Michigan Attorney General Nessel. This agreement resolves claims against the family, allocating funds for opioid prevention and recovery—including up to $105 million for Massachusetts—and highlights the Sackler family's conflicting public image. Their vast wealth, originating from OxyContin, is linked to a drug contributing to significant opioid-related deaths, despite individual Sackler family members largely avoiding personal lawsuits.

25Articles

Day 3652Start: May 2016

↑ 12 MayLast Change

Day 1 · 12 May 2016

NEWSstatnews.com

The man at the center of the secret OxyContin files

A Kentucky judge's order to unseal secret OxyContin records has brought attention to Dr. Richard Sackler, a former president of Purdue Pharma and a member of the controlling family. His testimony regarding OxyContin marketing is considered crucial evidence in a state lawsuit against Purdue for allegedly illegally marketing the potent opioid painkiller. This marks the first time a Sackler family member has been questioned under oath about OxyContin marketing.

Read full article ↗

THE SHADOW GAP: 530 days of silence

Day 531 · 25 October 2017

NEWSreuters.com

Opioid drugmaker Purdue Pharma faces U.S. investigation

Purdue Pharma LP confirmed it is under a U.S. investigation regarding its painkiller OxyContin. The drugmaker is simultaneously dealing with several lawsuits alleging its responsibility for the nation's opioid epidemic. This investigation adds to the legal challenges Purdue Pharma faces concerning its marketing and distribution practices.

Read full article ↗

THE SHADOW GAP: 111 days of silence

Day 642 · 13 February 2018

OPINIONThe Guardian

Meet the Sacklers: the family feuding over blame for the opioid crisis

The article examines the Sackler family's conflicting public image as philanthropists and their role in the opioid crisis through Purdue Pharma's OxyContin. Their vast wealth, funding their charitable donations, originates from a drug contributing to significant opioid-related deaths in America. While Purdue Pharma faced legal action, individual Sackler family members have largely avoided personal lawsuits.

Read full article ↗

THE SHADOW GAP: 1281 days of silence

Day 1923 · 17 August 2021

NEWSnytimes.com

Sacklers Threaten to Pull Out of Opioid Settlement Without Broad Legal Immunity

David Sackler stated that his family would withdraw their $4.5 billion pledge for an opioid settlement unless they receive broad legal immunity. This declaration came during a rare court appearance. The threat jeopardizes a significant financial contribution intended to address the opioid crisis.

Read full article ↗

THE SHADOW GAP: 15 days of silence

Day 1938 · 1 September 2021

DEVELOPMENTnpr.org

The Sacklers, Who Made Billions From OxyContin, Win Immunity From Opioid Lawsuits

A federal bankruptcy judge granted the Sackler family, owners of Purdue Pharma, sweeping immunity from opioid lawsuits related to OxyContin. This decision approves a bankruptcy settlement, shielding family members from liability for the opioid crisis. The ruling has drawn protest from demonstrators.

Read full article ↗

Day 1939 · 1 September 2021

NEWSbbc.com

Sackler family wins immunity from further opioid litigation

In September 2021, a US judge approved a bankruptcy plan for Purdue Pharma, which included a $4.5 billion payment from the Sackler family and granted them immunity from future opioid-related lawsuits. Despite strong opposition from some states, the settlement was approved, with Judge Robert Drain noting the Sacklers showed little remorse. This deal secured funds for the opioid crisis while controversially shielding the family from further litigation.

Read full article ↗

THE SHADOW GAP: 636 days of silence

Day 2575 · 30 May 2023

DEVELOPMENTcnn.com

Court grants Sackler family immunity in exchange for $6 billion opioid settlement

A New York court of appeals ruled that the Sackler family will be protected from current and future lawsuits regarding Purdue Pharma’s opioid business in exchange for a $6 billion settlement. This decision clears the way for a bankruptcy deal for Purdue Pharma, which is owned by the family. The settlement requires the Sacklers to pay billions to help fight the ongoing opioid epidemic and allows for the removal of their name from institutions under specific conditions.

Read full article ↗

Day 2575 · 31 May 2023

NEWSbbc.com

Sackler family wins immunity from opioid lawsuits

On May 31, 2023, the US Court of Appeals for the Second Circuit ruled that the Sackler family would receive full immunity from civil lawsuits related to the opioid crisis. This immunity is in exchange for a $6 billion settlement from the family, owners of Purdue Pharma. The ruling removes a key barrier to the settlement being paid out, which will fund opioid addiction treatment programs and compensate individual victims.

Read full article ↗

Day 2576 · 1 June 2023

NEWSnews.artnet.com

Price Database

The U.S. Second Circuit Court of Appeals in New York approved a deal requiring the Sackler family to pay $6 billion to combat the opioid crisis in exchange for civil lawsuit immunity. This ruling could facilitate the final approval of Purdue Pharma's bankruptcy settlement. Critics, including artist Nan Goldin and her organization Sackler P.A.I.N., oppose the immunity and have campaigned against the family's name in public institutions.

Read full article ↗

THE SHADOW GAP: 364 days of silence

Day 2940 · 30 May 2024

NEWSnpr.org

Supreme Court rejects controversial Purdue Pharma bankruptcy deal

The U.S. Supreme Court, in a 5-4 decision, invalidated Purdue Pharma's controversial bankruptcy deal that protected the Sackler family from opioid lawsuits. The ruling deemed the multi-billion-dollar settlement inappropriate, impacting the legal liability of the family. This decision follows years of protest by victims' relatives.

Read full article ↗

THE SHADOW GAP: 28 days of silence

Day 2968 · 27 June 2024

NEWSreuters.com

US Supreme Court blocks Purdue Pharma bankruptcy settlement

The U.S. Supreme Court blocked Purdue Pharma's bankruptcy settlement, which intended to shield the wealthy Sackler family owners from lawsuits. This ruling prevents the family from gaining immunity related to their role in the opioid epidemic. The decision impacts the legal resolution for thousands of opioid victims.

Read full article ↗

Day 2968 · 27 June 2024

NEWSfiercepharma.com

Billionaire Sackler family can't get legal immunity as part of Purdue bankruptcy deal, Supreme Court rules

The U.S. Supreme Court blocked a multi-billion-dollar bankruptcy agreement for Purdue Pharma and the Sackler family, denying the family immunity from civil opioid lawsuits. The proposed deal involved the Sacklers returning up to $6 billion, but the court ruled that bankruptcy courts lack authority to extinguish third-party claims without consent. This decision significantly impacts the long-running opioid settlement negotiations.

Read full article ↗

Day 2968 · 27 June 2024

NEWSarstechnica.com

SCOTUS tears down Sacklers’ immunity, blowing up opioid settlement

The US Supreme Court rejected an opioid settlement plan that would have granted the Sackler family lifetime immunity from further opioid-related litigation. This 5-4 ruling is a significant blow to the over 100,000 people affected by the opioid epidemic, delaying their compensation. The decision necessitates a restart of settlement talks, leaving the outcome and potential payouts uncertain.

Read full article ↗

THE SHADOW GAP: 658 days of silence

Day 3626 · 16 April 2026

NEWSopioidsettlementtracker.com

OST's Global Settlement Tracker — Opioid Settlement Tracker

The Opioid Settlement Tracker reports that Purdue Pharma is set to dissolve following court approval of its criminal sentence. Albertsons' potential $774 million opioid settlement is in negotiation, which would bring the global settlement total to $58.58 billion. In March 2026, $97.625 million was added from "Remnants" settlements involving regional pharmaceutical distributors and US local governments.

Read full article ↗

Day 3631 · 21 April 2026

DEVELOPMENTThe Guardian

Purdue Pharma expected to forfeit $225m as sentence in criminal opioids case

Purdue Pharma is expected to forfeit $225 million to the US Justice Department as part of a criminal opioids case, which paves the way for the company to finalize thousands of related lawsuits. This penalty is part of a 2020 pact, and the broader settlement, approved in November, requires the Sackler family to pay up to $7 billion. Purdue Pharma pleaded guilty to three federal criminal charges in November 2020, admitting to deceptive practices regarding OxyContin.

Read full article ↗

Day 3633 · 23 April 2026

NEWSpropublica.org

“A Punch in the Gut”: After Years of Waiting, Many Opioid Victims Will Be Shut Out of Purdue Settlement

Many opioid victims, including Mary Jannotta who lost her grandson to an overdose, will be excluded from the newly approved $7.4 billion Purdue Pharma bankruptcy plan. While $870 million is allocated for individual victims, tens of thousands will receive no compensation. This outcome follows the Supreme Court's 2024 rejection of an earlier settlement due to the Sacklers' immunity clause, highlighting ongoing challenges in achieving justice for all affected.

Read full article ↗

Day 3641 · 1 May 2026

DEVELOPMENTportal.ct.gov

Press Releases

Attorney General William Tong announced that Purdue Pharma will dissolve as a $7.4 billion opioid settlement with the company and the Sackler family became legally effective on May 1, 2026. This settlement, which permanently bars the Sacklers from selling opioids in the U.S., will distribute funds for addiction treatment and recovery over 15 years, with Connecticut set to receive $64 million. The development concludes nearly a decade of litigation by attorneys general nationwide.

Read full article ↗

Day 3641 · 1 May 2026

DEVELOPMENTmass.gov

Press Release $7.4 Billion Settlement With Purdue Pharma And Sackler Family Goes Into Effect

The Massachusetts Attorney General announced a $7.4 billion settlement with Purdue Pharma and the Sackler family is now legally effective. Massachusetts is set to receive up to $105 million for opioid prevention and recovery programs. Attorney General Andrea Joy Campbell hailed this as a milestone in holding the Sackler family accountable for the opioid crisis.

Read full article ↗

Day 3641 · 1 May 2026

NEWS11alive.com

$7.4B Purdue opioid settlement goes into effect after years of litigation

A $7.4 billion settlement with Purdue Pharma and the Sackler family over the opioid crisis has become legally effective after years of litigation. Purdue Pharma will be dissolved and replaced by a public-benefit company as part of the settlement, which aims to resolve thousands of lawsuits. This resolution follows a federal judge's criminal sentence to the company, acknowledging the impact on victims and the 900,000 deaths linked to the epidemic.

Read full article ↗

Day 3642 · 1 May 2026

DEVELOPMENTmichigan.gov

Purdue/Sackler $7.4 Billion Opioid Settlement Goes into Effect

Michigan Attorney General Dana Nessel announced that a $7.4 billion opioid settlement with Purdue Pharma and the Sackler family has become legally effective. This agreement, capping nearly a decade of investigations and litigation, will provide funds to communities, individual victims, and other groups across the country. The settlement follows Purdue's bankruptcy and a Supreme Court decision invalidating a prior agreement.

Read full article ↗

Day 3644 · 4 May 2026

NEWSelevenflo.com

Purdue Pharma: $7.4 Billion Plan Goes Effective, Knoa Pharma Begins Operations

Purdue Pharma's $7.4 billion settlement plan became legally effective on April 1, 2026, leading to the company's shutdown and the transition of its pharmaceutical operations to Knoa Pharma LLC. This marks the culmination of a Chapter 11 bankruptcy process that began in 2019 and involved multiple plan amendments. The new public-benefit company will continue operations while appeals and a contempt proceeding against Richard S. Sackler are pending.

Read full article ↗

Day 3648 · 8 May 2026

DEVELOPMENTportal.ct.gov

Press Releases

Attorney General William Tong announced a $7.4 billion settlement in principle between states, victims, the Sackler family, and Purdue Pharma regarding their role in the opioid crisis. This new settlement adds $1.4 billion and accelerates aid compared to a prior invalidated agreement. Multiple states, including Connecticut, New York, and California, led the negotiation efforts to fund opioid treatment and recovery.

Read full article ↗

Day 3648 · 8 May 2026

DEVELOPMENTattorneygenerallynnfitch.com

Purdue-Sackler Opioid Settlement Effective May 1 (May 8, 2026)

A press release from Mississippi's Attorney General confirmed that the Purdue-Sackler opioid settlement became effective on May 1. This development marks a significant step in the ongoing legal actions against Purdue Pharma and the Sackler family. The settlement aims to provide resources to address the widespread opioid crisis.

Read full article ↗

Day 3649 · 9 May 2026

NEWSeinpresswire.com

Purdue/Sackler $7.4 Billion Opioid Settlement Goes into Effect

A $7.4 billion settlement between Purdue Pharma, the Sackler family, and various states for their role in fueling the opioid crisis has gone into effect. Nevada is set to receive $57.9 million from the settlement, which culminates nearly a decade of litigation and investigations by attorneys general. This resolution will distribute funds to communities and individual victims, following a Supreme Court decision that invalidated previous settlement provisions.

Read full article ↗

Day 3652 · 12 May 2026

NEWSpharmaphorum.com

Judge rejects Purdue opioid settlement over Sackler family immunity

Judge Colleen McMahon rejected Purdue Pharma's bankruptcy plan, which offered the Sackler family immunity from civil lawsuits in exchange for a $4.5 billion payout. McMahon ruled that US bankruptcy law does not permit extinguishing claims against third parties without consent. This decision removes crucial legal protection for the Sacklers, impacting the settlement for opioid victims.

Read full article ↗